GLP-1 Evidence

Sigurnost

Nuspojave GLP-1: rangirane po učestalosti

Gastrointestinalne nuspojave su gotovo univerzalne i obično se mogu kontrolirati. Rijetki događaji koji dominiraju u medijskom izvještavanju zaista su rijetki.

Updated 3 min read 27 citations Evidence strength 4/5

Pogled iz zraka na bolnički krevet i ormarić u zajedničkoj bolničkoj sobi
玄史生 · CC0 · Wikimedia Commons

Česte nuspojave

Skoro sve učestale nuspojave su gastrointestinalne, i skoro sve izravno su posljedica odgođenog pražnjenja želuca. Obrazac je dosljedan u svim programima kliničkih ispitivanja [5][6][8]:

Tipični rasponi učestalosti iz randomiziranih ispitivanja
UčinakPribližna učestalostObrazac
MučninaVeoma često (trećina do polovica)Vrhunac doseže nakon svakog povećanja doze, zatim se povlači
DijarejaČestoČesto se javlja rano, obično prolazno
ZatvorČestoMože potrajati; često je dugoročno neugodnija tegoba
PovraćanjeČestoSnažno povezano s dozom
Bolovi u abdomenu, refluks, podrigivanjeČestoObično blago
Reakcije na mjestu injekcijeNeuobičajenoBlago
Prekid liječenja zbog nuspojavaNekoliko postoVeće kod najviših doza

Razlika između "trećina ljudi osjeća mučninu" i "nekoliko posto prekida liječenje" najkorisniji je podatak ovdje. Većina ljudi koji osjete mučninu izdrži je, obično zato što se stanje poboljša.

Rijetke nuspojave koje ljude brinu

Pankreatitis, bolesti žučnog mjehura, tumori C-stanica štitnjače i gastropareza dominiraju online raspravama znatno neproporcionalno u odnosu na njihovu učestalost u podacima.

  • Bolesti žučnog mjehura. Rizik je stvarno povećan, ali to je u velikoj mjeri posljedica samog naglog gubitka tjelesne težine, a ne izravne toksičnosti lijeka — nagli gubitak težine bilo kojim putem povećava rizik od žučnih kamenaca.
  • Pankreatitis. Intenzivno se nadzire u cijeloj skupini lijekova. Velike meta-analize ispitivanja kardiovaskularnih i bubrežnih ishoda nisu potvrdile signal na koji su upućivali rani prikazi slučajeva [1].
  • Tumori C-stanica štitnjače. Upozorenje potječe iz studija na glodavcima. Nije se pretočilo u dokazani signal kod ljudi, ali je zato razlog zbog kojeg su lijekovi kontraindicirani kod osobne ili obiteljske anamneze medularnog karcinoma štitnjače ili MEN2 sindroma.
  • Gastropareza. Odgođeno pražnjenje želuca namijenjeni je mehanizam djelovanja, kako je objašnjeno na stranici o mehanizmu djelovanja. Teška trajna gastropareza posve je drugačija i znatno rjeđa stvar.

Nepostojanje značajnih sigurnosnih signala u zbirnim podacima ispitivanja

Kako izgledaju noviji oralni lijekovi

Oralni agonisti malih molekula sada su prošli velika randomizirana ispitivanja i za pretilost i za rani tip 2 dijabetesa [2][3][4]. Njihov profil podnošljivosti sličan je injekcijskim oblicima — dominiraju isti gastrointestinalni učinci, uz istu strategiju postupnog povećanja doze. Činjenica da je riječ o tableti ne mijenja mehanizam djelovanja, pa time ne mijenja niti nuspojave. Više o oralnim opcijama.

Gdje se podaci iz ispitivanja i stvarni život razlikuju

Populacije u ispitivanjima su probrane, nadzirane i doza im se povećava po protokolu. Pregled iz 2025. o korištenju i učinkovitosti u stvarnom kliničkom okruženju utvrdio je da se opća slika sigurnosti održava i izvan ispitivanja, ali s više varijabilnosti — uzrokovane bržim povećanjem doze, prekidima doziranja, nestašicama opskrbe i pripravcima iz magistralne izrade neizvjesnog sadržaja [9]. Većina najgorih ishoda prijavljenih izvan ispitivanja povezana je s nabavom bez recepta, a ne sa samim lijekovima.

Bijele filmom obložene tablete u blister pakiranju
Cindy Shebley · CC BY 2.0 · Wikimedia Commons

Često postavljana pitanja

Prestaje li mučnina potpuno?
Kod većine ljudi povlači se u roku od nekoliko tjedana na određenoj dozi, a nakratko se vraća pri svakom povećanju. Zatvor je nuspojava koja najčešće potraje.
Je li gubitak kose nuspojava?
Opadanje kose dobro je poznata posljedica naglog gubitka tjelesne težine općenito — telogeni efluvij — a ne specifična toksičnost lijeka. Obično je privremeno.
Trebam li prekinuti uzimanje lijeka prije operacije?
Pitajte svog anesteziologa. Postoje posebne perioperativne smjernice jer želudac možda nije prazan nakon standardnog posta.
Znače li nuspojave da lijek djeluje?
Ne. I mučnina i gubitak težine povezani su s dozom, ali pojedinci se znatno razlikuju u oba pogleda. Mnogi ljudi izgube veliku količinu težine bez veće mučnine.
Dokazi na kojima se temelji ova stranica Stupičasti grafikon koji prikazuje sastav 16 publikacija citiranih na ovoj stranici prema vrsti studije. 31111meta-analysis (3)randomised trial (11)review (1)other (1)
16 publikacija, 2018.–2025. Riječ je o kombinaciji koja uključuje i ispitivanja i sinteze podataka, a to je pozicija iz koje je razumno iznositi tvrdnje o uzročnosti. Izvor: popis citata ove stranice, u nastavku.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  2. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  3. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  4. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stefanou MI, Theodorou A, Malhotra K, et al. · European stroke journal · 2024 · Meta-analysis DOIPubMed 38400569Full text
  5. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  6. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  7. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Rosenstock J, Yabe D, Cox D, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41765029
  8. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Cummings JL, Atri A, Sano M, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41865758
  9. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Buse JB, Bajaj HS, Dalskov SM, et al. · The lancet. Diabetes & endocrinology · 2026 · Randomised controlled trial DOIPubMed 42251859
  10. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Hannon TS, Chao LC, Barrientos-Pérez M, et al. · Lancet (London, England) · 2025 · Randomised controlled trial DOIPubMed 40975112
  11. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Rosenstock J, Hsia S, Nevarez Ruiz L, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544435
  12. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  13. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Blüher M, Rosenstock J, Hoefler J, et al. · Diabetologia · 2024 · Randomised controlled trial DOIPubMed 38095657Full text
  14. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Butler J, Shah SJ, Petrie MC, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 38599221Full text
  15. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  16. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Wharton S, Blevins T, Connery L, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37351564
  17. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Heise T, Mari A, DeVries JH, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468322
  18. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Inagaki N, Takeuchi M, Oura T, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35914543
  19. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  20. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34170647
  21. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Thomas MK, Nikooienejad A, Bray R, et al. · The Journal of clinical endocrinology and metabolism · 2021 · Randomised controlled trial DOIPubMed 33236115Full text
  22. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Yamada Y, Katagiri H, Hamamoto Y, et al. · The lancet. Diabetes & endocrinology · 2020 · Randomised controlled trial DOIPubMed 32333875
  23. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  24. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  25. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies Thomsen RW, Mailhac A, Løhde JB, et al. · Diabetes, obesity & metabolism · 2025 · Review DOIPubMed 40196933Full text
  26. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083
  27. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes Aroda VR, Rosenstock J, Terauchi Y, et al. · Diabetes care · 2019 · Journal article DOIPubMed 31186300

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original